ASX - By Stock
|
DGO |
Re:
Ann: Shareholder presentation - June 2020
|
|
alaedean
|
76 |
23K |
1 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
76
|
23K
|
1
|
|
ASX - By Stock
|
DGO |
Re:
Ann: Shareholder presentation - June 2020
|
|
alaedean
|
76 |
23K |
0 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
76
|
23K
|
0
|
|
ASX - By Stock
|
DGO |
Re:
Ann: Shareholder presentation - June 2020
|
|
alaedean
|
76 |
23K |
1 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
76
|
23K
|
1
|
|
ASX - By Stock
|
DGO |
Re:
Ann: Shareholder presentation - June 2020
|
|
alaedean
|
76 |
23K |
1 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
76
|
23K
|
1
|
|
ASX - By Stock
|
AGH |
Re:
Ann: MyAccess Clinics Enters Drug Science Project Twenty21
|
|
alaedean
|
24 |
8.2K |
4 |
24/06/20 |
24/06/20 |
ASX - By Stock
|
24
|
8.2K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Binding Term Sheet for distribution of CannEpil in Israel
|
|
alaedean
|
11 |
5.1K |
8 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
11
|
5.1K
|
8
|
|
ASX - By Stock
|
CPH |
Re:
Ann: Update on Mernova Sales License
|
|
alaedean
|
25 |
9.5K |
2 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
25
|
9.5K
|
2
|
|
ASX - By Stock
|
RGT |
Re:
Ann: 3,250 Prescriptions Milestone Surpassed
|
|
alaedean
|
50 |
18K |
10 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
50
|
18K
|
10
|
|
ASX - By Stock
|
RGT |
Re:
Ann: 3,250 Prescriptions Milestone Surpassed
|
|
alaedean
|
50 |
18K |
2 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
50
|
18K
|
2
|
|
ASX - By Stock
|
RGT |
Re:
Ann: 3,250 Prescriptions Milestone Surpassed
|
|
alaedean
|
50 |
18K |
15 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
50
|
18K
|
15
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: TasAlk to Manufacture Zeliras Insomnia and HOPE products
|
|
alaedean
|
13 |
5.4K |
5 |
26/05/20 |
26/05/20 |
ASX - By Stock
|
13
|
5.4K
|
5
|
|
ASX - By Stock
|
AGH |
Re:
Althea Group - Future Prospects
|
|
alaedean
|
290 |
189K |
3 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
290
|
189K
|
3
|
|
ASX - By Stock
|
AGH |
Re:
Althea Group - Future Prospects
|
|
alaedean
|
290 |
189K |
0 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
290
|
189K
|
0
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Trading Halt
|
|
alaedean
|
94 |
37K |
12 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
94
|
37K
|
12
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Pause in Trading
|
|
alaedean
|
7 |
2.8K |
7 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
7
|
2.8K
|
7
|
|
ASX - By Stock
|
AC8 |
Re:
Ann: AusCann Announces Leadership Change
|
|
alaedean
|
102 |
34K |
2 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
102
|
34K
|
2
|
|
ASX - By Stock
|
CPH |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
alaedean
|
7 |
3.3K |
0 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
7
|
3.3K
|
0
|
|
ASX - By Stock
|
DEG |
Re:
Ann: Trading Halt
|
|
alaedean
|
251 |
118K |
2 |
23/04/20 |
23/04/20 |
ASX - By Stock
|
251
|
118K
|
2
|
|
ASX - By Stock
|
CAN |
Re:
Ann: Cann executes supply agreement with Pure Cann NZ
|
|
alaedean
|
22 |
8.7K |
2 |
21/04/20 |
21/04/20 |
ASX - By Stock
|
22
|
8.7K
|
2
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19
|
|
alaedean
|
52 |
21K |
8 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
52
|
21K
|
8
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19
|
|
alaedean
|
52 |
21K |
4 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
52
|
21K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19
|
|
alaedean
|
52 |
21K |
5 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
52
|
21K
|
5
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19
|
|
alaedean
|
52 |
21K |
7 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
52
|
21K
|
7
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19
|
|
alaedean
|
52 |
21K |
10 |
17/04/20 |
17/04/20 |
ASX - By Stock
|
52
|
21K
|
10
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Pharma Signs Agreement Targeting Anti-Viral Treatments
|
|
alaedean
|
177 |
69K |
2 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
177
|
69K
|
2
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Pharma Signs Agreement Targeting Anti-Viral Treatments
|
|
alaedean
|
177 |
69K |
10 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
177
|
69K
|
10
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Pharma Signs Agreement Targeting Anti-Viral Treatments
|
|
alaedean
|
177 |
69K |
18 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
177
|
69K
|
18
|
|
ASX - By Stock
|
AGH |
Re:
Ann: Final Evidence Package Submitted to Health Canada
|
|
alaedean
|
7 |
4.1K |
4 |
07/04/20 |
07/04/20 |
ASX - By Stock
|
7
|
4.1K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Pharma COVID-19 Business and Operations Update
|
|
alaedean
|
73 |
34K |
11 |
06/04/20 |
06/04/20 |
ASX - By Stock
|
73
|
34K
|
11
|
|
ASX - By Stock
|
AC8 |
Re:
Ann: AusCann to Commence Clinical Trial and Product Distribution
|
|
alaedean
|
64 |
28K |
12 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
64
|
28K
|
12
|
|
ASX - By Stock
|
RGT |
JV Swiss Company FOUND
|
|
alaedean
|
2 |
1.9K |
5 |
28/03/20 |
28/03/20 |
ASX - By Stock
|
2
|
1.9K
|
5
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Voluntary Suspension Extension
|
|
alaedean
|
36 |
11K |
1 |
26/03/20 |
26/03/20 |
ASX - By Stock
|
36
|
11K
|
1
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Voluntary Suspension Extension
|
|
alaedean
|
36 |
11K |
2 |
26/03/20 |
26/03/20 |
ASX - By Stock
|
36
|
11K
|
2
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Voluntary Suspension Extension
|
|
alaedean
|
36 |
11K |
0 |
26/03/20 |
26/03/20 |
ASX - By Stock
|
36
|
11K
|
0
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Voluntary Suspension Extension
|
|
alaedean
|
36 |
11K |
8 |
26/03/20 |
26/03/20 |
ASX - By Stock
|
36
|
11K
|
8
|
|
ASX - By Stock
|
AGH |
Re:
Ann: Appendix 4C - quarterly
|
|
alaedean
|
10 |
7.3K |
4 |
29/01/20 |
29/01/20 |
ASX - By Stock
|
10
|
7.3K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Supply Agreement with THC Global for Canndeo Products
|
|
alaedean
|
6 |
4.3K |
11 |
20/01/20 |
20/01/20 |
ASX - By Stock
|
6
|
4.3K
|
11
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Pharma Crosses 2,000 Prescription Milestone
|
|
alaedean
|
36 |
21K |
10 |
09/01/20 |
09/01/20 |
ASX - By Stock
|
36
|
21K
|
10
|
|
ASX - By Stock
|
AC8 |
Re:
Ann: AusCann Releases Hard-shell Capsules to Clinical Evaluation
|
|
alaedean
|
50 |
29K |
4 |
18/12/19 |
18/12/19 |
ASX - By Stock
|
50
|
29K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Approval Received for Distribution of CannEpil into Ireland
|
|
alaedean
|
51 |
17K |
6 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
51
|
17K
|
6
|
|
ASX - By Stock
|
AGH |
Re:
Ann: 2019 AGM CEO Address
|
|
alaedean
|
7 |
5.3K |
3 |
27/11/19 |
27/11/19 |
ASX - By Stock
|
7
|
5.3K
|
3
|
|
ASX - By Stock
|
AGH |
Re:
Ann: 2019 AGM CEO Address
|
|
alaedean
|
7 |
5.3K |
9 |
27/11/19 |
27/11/19 |
ASX - By Stock
|
7
|
5.3K
|
9
|
|
ASX - By Stock
|
RGT |
Re:
Ann: Binding Term Sheet to Immediately Expand into Latin America
|
|
alaedean
|
70 |
26K |
7 |
22/11/19 |
22/11/19 |
ASX - By Stock
|
70
|
26K
|
7
|
|
ASX - By Stock
|
ZIP |
Re:
Ann: Zip Strikes Strategic Agreement with Amazon Australia
|
|
alaedean
|
346 |
224K |
7 |
07/11/19 |
07/11/19 |
ASX - By Stock
|
346
|
224K
|
7
|
|
ASX - By Stock
|
AC8 |
Re:
Ann: AusCann Effects Board Changes
|
|
alaedean
|
6 |
4.7K |
8 |
04/11/19 |
04/11/19 |
ASX - By Stock
|
6
|
4.7K
|
8
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: September 2019 Quarterly Report
|
|
alaedean
|
26 |
17K |
4 |
31/10/19 |
31/10/19 |
ASX - By Stock
|
26
|
17K
|
4
|
|
ASX - By Stock
|
RGT |
Re:
Ann: September Quarterly Activity and Cashflow Report
|
|
alaedean
|
71 |
39K |
20 |
31/10/19 |
31/10/19 |
ASX - By Stock
|
71
|
39K
|
20
|
|
ASX - By Stock
|
RGT |
Re:
Ann: MGC Reaches 1,000 Prescription Milestone Ahead of Schedule
|
|
alaedean
|
81 |
29K |
13 |
31/10/19 |
31/10/19 |
ASX - By Stock
|
81
|
29K
|
13
|
|
ASX - By Stock
|
RGT |
Re:
News to come
|
|
alaedean
|
47 |
21K |
1 |
30/10/19 |
30/10/19 |
ASX - By Stock
|
47
|
21K
|
1
|
|
ASX - By Stock
|
AC8 |
Re:
Ann: September 2019 Quarterly Activities and Cashflow Reports
|
|
alaedean
|
18 |
6.9K |
2 |
25/10/19 |
25/10/19 |
ASX - By Stock
|
18
|
6.9K
|
2
|
|